Portfolio

Dr. Zhen Li, PhD

is a clinical-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA therapeutics to treat a broad spectrum of diseases.

Paul Blanchfield

Alpha-9 is a leading, clinical stage radiopharmaceutical company, advancing a distinctive portfolio of molecules. Using targeted, bespoke molecules, we treat cancer cells with unparalleled precision.

Dr. David Ke, MD

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.

Peter S. Lawrence

Cardurion is a next-generation cardiovascular company that is taking a bold and innovative approach to addressing the unmet needs of people suffering from and at risk of heart disease.

Dr. Tom Miller, PhD

Iambic Therapeutics is a clinical-stage biotechnology company specializing in AI-driven drug discovery, recently collaborating with Revolution Medicines to develop novel oncology drug candidates.

Nima Farzan

Latigo is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.

Dr. Gary Glick, PhD

We have established a replicable and scalable model for drug discovery and development and are advancing a diversified portfolio of programs with the intention of efficiently delivering safe and effective medicines to patients with autoimmune and inflammatory diseases.

Dr. Mani Subramanian, MD/PhD

is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, NASH, and more.

Dr. Patrick Troger, PhD

TRIANA Biomedicines is leading a transformative approach to discover and develop novel therapeutics to treat diseases by unlocking the full potential of molecular glues.

Vishal Patel, PhD

Triveni Bio is a clinical-stage biotech company taking a genetics-informed approach and leveraging advanced antibody engineering to build first-in-class therapeutics that will redefine treatment paradigms for immune and inflammatory diseases.

Dr. Dominik Schumacher, PhD

Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models.